Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLOMID vs CLOMIPHENE CITRATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Competitive antagonist of estrogen receptors (ER) in hypothalamus and pituitary, leading to increased gonadotropin-releasing hormone (Gn RH) and subsequent LH and FSH release, stimulating ovulation.
Selective estrogen receptor modulator; competes with estrogen for binding at estrogen receptors in the hypothalamus, inhibiting negative feedback and increasing gonadotropin-releasing hormone (Gn RH) secretion, leading to increased LH and FSH release from the pituitary.
Treatment of ovulatory dysfunction in women desiring pregnancy (FDA approved),Off-label: treatment of male infertility (oligospermia)
Treatment of ovulatory dysfunction in women desiring pregnancy,Off-label: male infertility (oligospermia), induction of ovulation in assisted reproductive technology
50 mg orally once daily for 5 days, starting on day 5 of the menstrual cycle. May increase to 100 mg daily if no response.
50 mg orally once daily for 5 days, starting on day 5 of menstrual cycle; may increase to 100 mg orally once daily for 5 days if ovulation not achieved.
Terminal half-life is 5–7 days for zuclomiphene (active isomer), with prolonged elimination due to enterohepatic recirculation.
Terminal elimination half-life is approximately 5–7 days (120–168 hours) for the active zu-isomer, with a longer half-life for its metabolites. This prolonged half-life leads to accumulation with repeated dosing and sustained clinical effects.
Hepatic via CYP3A4 and CYP2D6; undergoes enterohepatic circulation; terminal half-life ~5-7 days
Hepatic metabolism; excreted in feces; active metabolites (possibly enterohepatic recirculation).
Primarily hepatic metabolism; metabolites excreted in feces (42%) and urine (8% unchanged).
Primarily fecal (approximately 50%), with about 8% renal excretion of unchanged drug and metabolites. Biliary excretion is significant, with enterohepatic recirculation contributing to prolonged elimination.
Highly protein bound (>99%), primarily to albumin.
Approximately 80–90% bound to albumin, with significant binding to other plasma proteins including sex hormone-binding globulin (SHBG).
Not well-characterized; limited data suggest a large Vd (>100 L) due to extensive tissue distribution.
Apparent volume of distribution is large, approximately 50–100 L/kg, indicating extensive tissue distribution and accumulation, particularly in the liver and reproductive organs.
Oral bioavailability is approximately 50% due to first-pass metabolism.
Oral: ~100% absorbed, but bioavailability is difficult to quantify due to extensive first-pass metabolism and enterohepatic cycling; essentially complete systemic exposure after oral administration.
No specific adjustment required; use caution in severe impairment (Cr Cl <30 m L/min) as data limited.
No specific dose adjustment guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment, no adjustment recommended, but monitor liver function.
Contraindicated in patients with liver disease or hepatic dysfunction; no Child-Pugh based adjustments available.
Not indicated for use in children; safety and efficacy not established.
Not recommended for use in children; safety and efficacy not established.
Not indicated for postmenopausal women. Use not recommended in elderly due to lack of efficacy in anovulation.
Not indicated for use in elderly patients; no specific dosing recommendations.
None
Should not be used in patients with liver disease or abnormal uterine bleeding of undetermined origin.
Ovarian hyperstimulation syndrome (OHSS),Ovarian enlargement,Visual disturbances (especially with prolonged use),Multiple pregnancy (increased risk),Ectopic pregnancy,Ovarian cancer risk (theoretical, based on prolonged use)
Ovarian enlargement/cysts; visual disturbances; multiple pregnancy; ovarian hyperstimulation syndrome; vasomotor symptoms; blurred vision; prolonged use may increase risk of borderline or invasive ovarian tumors.
Pregnancy (Category X),Liver disease or dysfunction,Undiagnosed abnormal vaginal bleeding,Ovarian cyst or enlargement not due to polycystic ovary syndrome,Hypersensitivity to clomiphene or components
Pregnancy; liver disease or history; abnormal uterine bleeding of undetermined origin; ovarian cyst or enlargement due to polycystic ovary syndrome; hypersensitivity to clomiphene.
No specific food interactions. Avoid grapefruit as it may alter metabolism (theoretical due to CYP3A4 involvement).
No significant food interactions. Avoid excessive alcohol consumption as it may impair fertility.
Clomiphene citrate is contraindicated in pregnancy. It is associated with an increased risk of fetal malformations, including neural tube defects, specifically when exposure occurs during the first trimester. Second and third trimester risks are not well studied due to contraindication, but theoretical risks include ovarian hyperstimulation syndrome (OHSS) effects on pregnancy.
FDA Pregnancy Category X. Clomiphene citrate is contraindicated in pregnancy. First trimester exposure associated with neural tube defects, cleft palate, and syndactyly. Second and third trimester: no data due to contraindication. Risk of multiple gestation (5-12%) increases risks of preterm labor, low birth weight, and congenital anomalies.
Safety in breastfeeding is not established. Clomiphene may reduce milk production. The M/P ratio is unknown. It is generally not recommended during breastfeeding.
Excreted into breast milk; M/P ratio unknown. Clomiphene may reduce milk production due to anti-estrogenic effects. Because of potential for adverse reactions in nursing infants, women are advised not to breastfeed during treatment.
No dose adjustments are relevant as clomiphene is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy are not applicable due to contraindication.
No dose adjustments in pregnancy as drug is contraindicated. If pregnancy occurs, discontinue immediately. No pharmacokinetic studies in pregnant women; drug should not be used.
Monitor ovarian size via ultrasound to reduce risk of ovarian hyperstimulation syndrome (OHSS). Limit course to 3-6 cycles due to increased risk of ovarian tumors. Check pregnancy test before each cycle. Use with caution in liver disease.
Monitor ovarian size and estradiol levels to reduce risk of ovarian hyperstimulation syndrome (OHSS). Use only in patients with ovulatory dysfunction; rule out pregnancy before each cycle. Limit to 6 treatment cycles due to increased risk of ovarian cancer with prolonged use.
Take exactly as prescribed, typically 50 mg daily for 5 days starting on day 5 of menstrual cycle.,Report abdominal pain, bloating, nausea, or weight gain (possible OHSS).,Avoid alcohol due to hepatotoxicity risk.,Most pregnancies occur within first 3 cycles; consider alternative after 6 cycles.,May cause visual disturbances; report blurred vision or spots.
Take clomiphene citrate exactly as prescribed, typically for 5 days starting on day 3-5 of menstrual cycle.,Ovulation usually occurs 5-10 days after the last dose; have intercourse every other day during this window.,Common side effects include hot flashes, mood swings, and visual disturbances; report persistent visual changes immediately.,Risk of multiple pregnancy (mainly twins) is increased; discuss with healthcare provider.,Avoid use if pregnant, have liver disease, or have abnormal vaginal bleeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLOMID vs CLOMIPHENE CITRATE, answered by our medical review team.
CLOMID is a Selective Estrogen Receptor Modulator that works by Competitive antagonist of estrogen receptors (ER) in hypothalamus and pituitary, leading to increased gonadotropin-releasing hormone (Gn RH) and subsequent LH and FSH release, stimulating ovulation.. CLOMIPHENE CITRATE is a Selective Estrogen Receptor Modulator (SERM) that works by Selective estrogen receptor modulator; competes with estrogen for binding at estrogen receptors in the hypothalamus, inhibiting negative feedback and increasing gonadotropin-releasing hormone (Gn RH) secretion, leading to increased LH and FSH release from the pituitary.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLOMID and CLOMIPHENE CITRATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLOMID is: 50 mg orally once daily for 5 days, starting on day 5 of the menstrual cycle. May increase to 100 mg daily if no response.. The standard adult dose of CLOMIPHENE CITRATE is: 50 mg orally once daily for 5 days, starting on day 5 of menstrual cycle; may increase to 100 mg orally once daily for 5 days if ovulation not achieved.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLOMID and CLOMIPHENE CITRATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLOMID is classified as Category C. Clomiphene citrate is contraindicated in pregnancy. It is associated with an increased risk of fetal malformations, including neural tube defects, specifically when exposure occurs. CLOMIPHENE CITRATE is classified as Category A/B. FDA Pregnancy Category X. Clomiphene citrate is contraindicated in pregnancy. First trimester exposure associated with neural tube defects, cleft palate, and syndactyly. Second and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.